Table 3.

Characteristics of patients who are alive

Patient	Age	Performance score	Disease status at transplant	Donor/graft	Conditioning regimen	Acute GVHD	Chronic GVHD	Time to last contact
24	9	100	relapse	Matched relative, BM	TBI (800 cGy fractionated) + Bu + Cy		extensive	131 months
25	12	100	CR3	MSD, BM	Bu (8 mg/kg) + Cy + etoposide			100 months
26	16	80	CR1	MSD, BM	Cy + etoposide			67 months
27	6	100	relapse	MSD, BM	Cy + ARAC + Mel (140 mg/m2)			57 months
28	7	100	CR3	MSD, PBPC	Cy + ARAC + Mel (142 mg/m2)		extensive	48 months
29	12	100	CR3	Unrelated, PBPC	Bu (7 mg/kg) + FLU + ATG			16 months
30*	14	80	CR1	Unrelated, CB	TBI (200 cGy) + Cy + FLU + ATG	grade 3		25 months
31	6	Not reported	CR2	Unrelated, CB	TBI (200 cGy) + Cy + FLU + ATG	grade 2		8 months
32	9	100	CR2	Unrelated, CB	TBI (200 cGy) + Cy + FLU + ATG	grade 2	limited	4 months
33	15	90	CR1	MSD, PBPC	Bu (4 mg/kg) + FLU			3 months
34	16	100	CR2	MSD, PBPC	FLU + Mel (140 mg/m2)			3 months
35	7	80	CR2	Unrelated, PBPC	Bu (5 mg/kg) + FLU + ATG			36 months
36*	3	80	relapse	Unrelated, BM	TBI (450 cGy) + Cy + alemtuzumab			37 months
37	13	70	CR1	Unrelated, PBPC	TBI (200 cGy) + FLU	grade 3	extensive	61 months
38	13	100	unknown	Unrelated, PBPC	FLU + Mel (137 mg/m2)	grade 3	extensive	24 months

Abbreviations: CR = complete remission; BM = bone marrow; PBPC = peripheral blood progenitor cells; MSD = matched sibling donor; TBI = total body irradiation; Bu = busulfan; Cy = cyclophosphamide; Mel = melphalan; FLU = fludarabine; ATG = anti-thymocyte globulin

Intervention post RIC HCT and outcome

^*Patient # 30: Second HCT (same donor, TBI 1200 cGY + Cy) for leukemia relapse 21 months after RIC HCT, leukemia relapse and third HCT 36 months after second HCT. Patient is alive, 4 months from the third HCT

^*Patient # 36: DLI for cytogenetic relapse 4 months after RIC HCT, and alive, 33 months after DLI